Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

Bavarian Nordic has won US Food and Drug Administration (FDA) approval for its chikungunya vaccine Vimkunya, becoming the ...

There are now two vaccines to protect against chikungunya approved for use in the US, with Bavarian Nordic Vimkunya becoming the first cleared for use in adolescents. The Danish biopharma company ...

Bavarian Nordic aims to provide commercial availability ... by the European Commission. About VIMKUNYA™ (Chikungunya Vaccine, Recombinant)VIMKUNYA is a vaccine for prevention of disease caused ...

Discover why BVNKF's vaccine innovations, growth catalysts, and compelling valuation after a 52% pullback make it a strong ...

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine approved in Europe for individuals as young as 12 years old. Vimkunya is a ...

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – ...

Commercial for North America at Bavarian Nordic. “As the first virus-like particle single-dose, pre-filled syringe chikungunya vaccine, Vimkunya provides a crucial new tool to help protect at ...

COPENHAGEN, Denmark, February 14, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for ...